Keiko Minashi
About
Keiko Minashi is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology.
According to data from OpenAlex, Keiko Minashi has authored 118 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 90 papers in Pulmonary and Respiratory Medicine, 79 papers in Surgery and 39 papers in Oncology. Recurrent topics in Keiko Minashi's work include Gastric Cancer Management and Outcomes (69 papers), Esophageal Cancer Research and Treatment (52 papers) and Esophageal and GI Pathology (28 papers). Keiko Minashi is often cited by papers focused on Gastric Cancer Management and Outcomes (69 papers), Esophageal Cancer Research and Treatment (52 papers) and Esophageal and GI Pathology (28 papers). Keiko Minashi collaborates with scholars based in Japan, United States and Taiwan. Keiko Minashi's co-authors include Atsushi Ohtsu, Manabu Muto, Tomonori Yano, Ken Kato, Satoshi Ishikura, Narikazu Boku, Kei Muro, Takashi Kojima, Haruhiko Fukuda and Yoshito Komatsu and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and The Lancet Oncology.
In The Last Decade
Keiko Minashi
108 papers receiving 3.4k citations
Hit Papers
Peers
Keiko Minashi
Hiromasa Fujita Japan
Wataru Takiyama Japan
Christian A. Gutschow Germany
Naomi Kakushima Japan
Wolfgang Schröder Germany
Boudewijn E. C. Plaat Netherlands
Jonathan J. Beitler United States
Seung-Il Park South Korea
Grant Fullarton United Kingdom
Heiji Yoshinaka Japan
Citations per year, relative to Keiko Minashi Keiko Minashi (= 1×)
peers
Hiromasa Fujita
Countries citing papers authored by Keiko Minashi
Since
Specialization
Citations
This map shows the geographic impact of Keiko Minashi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keiko Minashi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keiko Minashi more than expected).
Fields of papers citing papers by Keiko Minashi
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Keiko Minashi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keiko Minashi. The network helps show where Keiko Minashi may publish in the future.
Co-authorship network of co-authors of Keiko Minashi
This figure shows the co-authorship network connecting the top 25 collaborators of Keiko Minashi. A scholar is included among the top collaborators of Keiko Minashi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keiko Minashi. Keiko Minashi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Nakanishi, Koki, Naotoshi Sugimoto, Yasuhiro Kodera, et al.. (2025). Prognostic factors and treatment response in HER2-positive gastric cancer patients receiving trastuzumab deruxtecan: secondary analysis of the EN-DEAVOR study. PubMed. 8. 100184–100184.
2.
Sakai, Daisuke, Shigenori Kadowaki, Ryohei Kawabata, et al.. (2025). Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial. Journal of Clinical Oncology. 43(19). 2196–2207.
3.
Kadowaki, Shigenori, Tomoyuki Otsuka, Keiko Minashi, et al.. (2025). An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study. Gastric Cancer. 28(5). 955–967.
4.
Ohashi, Shinya, et al.. (2025). Nivolumab with definitive chemoradiotherapy for oesophageal squamous cell carcinoma (NOBEL): a multicentre, single-arm, phase 2 feasibility trial. EClinicalMedicine. 91. 103689–103689.
5.
Muto, Manabu, Katsuyuki Sakanaka, Shinya Ohashi, et al.. (2024). Effect of nivolumab combined with definitive chemoradiotherapy on response rate for esophageal cancer: An immune active intrinsic subtype could be its biomarker—The NOBEL trial.. Journal of Clinical Oncology. 42(16_suppl). 4068–4068.
6.
Takahari, Daisuke, N. Yamamoto, Akira Ooki, et al.. (2023). 1561P APC mutation (mt.), MYC, and GATA6 amplifications (amp.) were associated with worse survival in HER2-positive advanced gastric cancer patients treated with S-1/capecitabine plus oxaliplatin combined with trastuzumab (T-mab) and nivolumab (N-mab). Annals of Oncology. 34. S873–S874.
7.
Satoh, Taroh, Ken Kato, Takashi Ura, et al.. (2021). Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma (ATTRACTION-1/ONO-4538-07). Esophagus. 18(4). 835–843.
8.
Kadota, Tomohiro, Keiko Minashi, Masashi Wakabayashi, et al.. (2021). Diagnostic yield of conventional endoscopy with endoscopic ultrasonography for submucosal invasion of superficial esophageal squamous cell carcinoma: a post hoc analysis of multicenter prospective confirmatory study (JCOG0508). Esophagus. 18(3). 604–611.
9.
Kato, Ken, Yuichiro� Doki, Takashi Ura, et al.. (2020). Long‐term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer. Cancer Science. 111(5). 1676–1684.
10.
Hironaka, Shuichi, Azusa Komori, Ryunosuke Machida, et al.. (2020). The association of primary tumor site with acute adverse event and efficacy of definitive chemoradiotherapy for cStage II/III esophageal cancer: an exploratory analysis of JCOG0909. Esophagus. 17(4). 417–424.
11.
Nakajima, Takako Eguchi, Shigenori Kadowaki, Keiko Minashi, et al.. (2020). Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer. Clinical Cancer Research. 27(4). 1029–1036.
12.
Fujii, Satoshi, Masayuki Komatsu, Mari Takahashi, et al.. (2020). CD24 and CK4 are upregulated by SIM2, and are predictive biomarkers for chemoradiotherapy and surgery in esophageal cancer. International Journal of Oncology. 56(3). 835–847.
13.
Morizane, Chigusa, Makoto Ueno, Masahiro Tajika, et al.. (2020). 128P Clinical update with plasma and tumour-based genomic analyses in expansion part of phase I study of selective FGFR inhibitor E7090. Annals of Oncology. 31. S1292–S1293.
14.
Tamaoki, Masashi, Masayuki Komatsu, Keiko Minashi, et al.. (2018). Multiple roles of single‐minded 2 in esophageal squamous cell carcinoma and its clinical implications. Cancer Science. 109(4). 1121–1134.
15.
Kang, Y-K., Ken Kato, Hyun Cheol Chung, et al.. (2017). Interim safety and clinical activity of nivolumab (Nivo) in combination with S-1/capecitabine plus oxaliplatin in patients (pts) with previously untreated unresectable advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: part 1 study of ATTRACTION-04 (ONO-4538-37). Annals of Oncology. 28. v228–v229.
16.
Kudo, Toshihiro, Yasuo Hamamoto, Ken Kato, et al.. (2017). Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. The Lancet Oncology. 18(5). 631–639.
17.
Kaneko, Kazuhiro, Tomonori Yano, Keiko Minashi, et al.. (2012). Treatment Strategy for Superficial Pharyngeal Squamous Cell Carcinoma Synchronously Combined with Esophageal Cancer. Oncology. 84(1). 57–64.
18.
Tu, Chia‐Hung, Manabu Muto, Takahiro Horimatsu, et al.. (2010). Submucosal tumor appearance is a useful endoscopic predictor of early primary-site recurrence after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Diseases of the Esophagus. 24(4). 274–278.
19.
Kurokawa, Yukinori, Manabu Muto, Keiko Minashi, Narikazu Boku, & Haruhiko Fukuda. (2009). A Phase II Trial of Combined Treatment of Endoscopic Mucosal Resection and Chemoradiotherapy for Clinical Stage I Esophageal Carcinoma: Japan Clinical Oncology Group Study JCOG0508. Japanese Journal of Clinical Oncology. 39(10). 686–689.
20.
Kawamura, Osamu, Masami Murakami, Takuro Yamada, et al.. (2003). Relationship between gastric disease and deletion of cag pathogenicity island genes of Helicobacter pylori in gastric juice.. Digestive Diseases and Sciences. 48(1). 47–53.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Hiromasa Fujita Breakdown of academic impact, for papers by Wataru Takiyama Breakdown of academic impact, for papers by Christian A. Gutschow Breakdown of academic impact, for papers by Naomi Kakushima Breakdown of academic impact, for papers by Wolfgang Schröder Breakdown of academic impact, for papers by Boudewijn E. C. Plaat Breakdown of academic impact, for papers by Jonathan J. Beitler Breakdown of academic impact, for papers by Seung-Il Park Breakdown of academic impact, for papers by Grant Fullarton Breakdown of academic impact, for papers by Heiji Yoshinaka